UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2025

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware001-4182285-4027995(State or other jurisdiction of incorporation)(Commission (I. R. S. Employer Identification No.)

1119 Keystone Way N. #201 Carmel, IN 46032

(Address of principal executive offices, including zip code)

(463) 345-8950

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule $14d-2(b)$ under the Exchange Act (17 CFR $240.14d-2(b)$)
Pre-commencement communications pursuant to Rule $13\text{e-}4(c)$ under the Exchange Act (17 CFR $240.13\text{e-}4(c)$)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.001 par value	SYRA	The Nasdag Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging	arowth	company	7 П
Linciging	growuii	company	/ 11

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 8.01. Other Events.

On April 7, 2025, Andrew Dahlem, a current director of Syra Health Corp. (the "Company"), agreed to become Chairman of the Board of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYRA HEALTH CORP.

Date: April 8, 2025

By:/s/ Deepika Vuppalanchi
Deepika Vuppalanchi
Chief Executive Officer